Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX…
Posted: January 29, 2021 at 4:50 pm
RALEIGH, N.C., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a specialty pharmaceutical company focusing on treating conditions that are primarily associated with testosterone deficiency, today announced that it has appointed Himanshu H. Shah and Shalin Shah as co-CEOs to drive the next phase of growth as the company looks to a potential launch of KYZATREX in Q4 2021 and further the development of Marius deep clinical pipeline.
Himanshu H. Shah brings over 30 years of experience across global capital markets and will continue his role as chairman of the board in addition to co-CEO. He has advised numerous public and private companies over the past decades to help them unlock substantial shareholder value and execute both innovative and pragmatic business strategies.
I am proud to continue serving Marius and work on developing the best treatment options for men with hypogonadism, a common but not widely discussed disease among patients and prescribers, said Himanshu H. Shah, chairman and co-CEO of Marius Pharmaceuticals. Misconceptions about hypogonadism are having a huge impact on the health of millions of men globally and costing the U.S. healthcare system alone billions of dollars annually. There is a huge opportunity for Marius to address these issues and drastically alter the testosterone therapy landscape.
Shalin Shah will also step into the role of co-CEO from chief financial officer and executive vice president of strategy for Marius. Shalin has been integral in driving overall strategy at Marius for the past four years and will oversee the growth of the team and execution of innovative models as it expands both clinically and commercially to become a leading pharmaceutical company.
I am excited for the opportunity to serve Marius in this new capacity, especially at a time when the world is seeing technology and healthcare intersect more than ever, truly helping patients, said Shalin Shah, co-CEO of Marius Pharmaceuticals. I am confident in Marius mission to better the lives of patients by ensuring adequate levels of testosterone and enhance patient care through disruptive technologies and personalization.
Om Dhingra, Ph.D., led the company from initial development of the lead compound through two successful Phase 3 clinical trials and will move into the role of vice chairman. He will help guide the companys clinical development plan and ensure KYZATREX and its differentiating safety and efficacy data is well known in the medical world.
It has been my great pleasure serving the company as CEO. I am very proud of the data we have generated, which we believe will position KYZATREX as the standard of care for patients suffering from hypogonadism globally, said Dr. Om Dhingra, vice chairman of Marius Pharmaceuticals.
If approved by the FDA, KYZATREX has the potential to become the new standard of care for treating patients with hypogonadism. Testosterone is a crucial hormone that is essential to sexual and reproductive health, but also has important functions in metabolic, inflammatory, cardiovascular and neurological health. In the U.S. there are at least six million symptomatic men suffering from hypogonadism, and over 100 million men globally. The resulting medical costs associated with men with untreated hypogonadism and related comorbidities are more than $25 billion in the U.S. alone. Current treatments on the market are dominated by therapies with unappealing administration methods, including auto-injections, in-office infusions and topical gels and creams that have a high transference risk. KYZATREX is an orally administered treatment that avoids the drawbacks that keep men from continuing treatment on available testosterone therapies.
About KYZATREX KYZATREX if approved, will represent a novel oral testosterone replacement therapy option for adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).
The ReTUNE study was a multi-center, 12-month study across the U.S. that studied the safety and efficacy of KYZATREX in hypogonadal subjects (total testosterone 281 ng/dL). Efficacy was determined by number of subjects in the normal, eugonadal range after 90 days of treatment, including dose titrations, while safety was monitored for a further 9 months while on a steady dose. In addition to testosterone parameters, the study collected Patient Reported Outcomes (PROs), which showed statistically significant results both from baseline and against its comparator. A pivotal six-month Phase 3 study was conducted, in which subjects were monitored using ABPM, now considered the standard BP assessment by the FDA and clinical experts. An improved dose regimen was also used in the pivotal six-month Phase 3 study. The results of the Phase 3 studies will be published in leading medical journals and presented at national conferences in 2021.
The FDA has conditionally accepted KYZATREX as the trade name for this investigational drug. The safety and efficacy have not been fully evaluated by any regulatory authority.
About Marius PharmaceuticalsMarius is a specialty pharmaceutical company focusing on treating conditions that are primarily associated with hypogonadism, commonly referred to as testosterone deficiency. The companys mission is to improve the functional lives of patients and reduce the risks of the downstream effects of endocrine imbalance by ensuring appropriate level of testosterone. For more information, please visit http://www.mariuspharma.com.
Media Contact: Emily Brice919-610-3319ebrice@fwv-us.com
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/f825d70b-874a-4cef-9160-429f83bbfc66
https://www.globenewswire.com/NewsRoom/AttachmentNg/ba2569ca-0922-4b49-8d68-49424b5e44d4
Himanshu H. Shah
Co-CEO and Chairman of the Board, Marius Pharmaceuticals
Shalin Shah
Co-CEO, Marius Pharmaceuticals
Follow this link:
Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX...
- What is Male Hypogonadism? Learn Hormone.org's ... [Last Updated On: May 4th, 2015] [Originally Added On: May 4th, 2015]
- Prevalence, Diagnosis and Treatment of Hypogonadism in ... [Last Updated On: May 4th, 2015] [Originally Added On: May 4th, 2015]
- Hypogonadism: Types, Causes, & Symptoms Healthline [Last Updated On: May 4th, 2015] [Originally Added On: May 4th, 2015]
- Hypogonadism - Wikipedia, the free encyclopedia [Last Updated On: May 4th, 2015] [Originally Added On: May 4th, 2015]
- Hypogonadotropic hypogonadism - Wikipedia, the free ... [Last Updated On: May 12th, 2015] [Originally Added On: May 12th, 2015]
- Male hypogonadism Tests and diagnosis - Mayo Clinic [Last Updated On: May 25th, 2015] [Originally Added On: May 25th, 2015]
- Male hypogonadism Symptoms - Mayo Clinic [Last Updated On: May 29th, 2015] [Originally Added On: May 29th, 2015]
- Male hypogonadism: Symptoms and treatment [Last Updated On: June 13th, 2015] [Originally Added On: June 13th, 2015]
- Low Testosterone in Men | Hypogonadism [Last Updated On: June 19th, 2015] [Originally Added On: June 19th, 2015]
- hypogonadism | pathology | Britannica.com [Last Updated On: July 23rd, 2015] [Originally Added On: July 23rd, 2015]
- Hypergonadotropic hypogonadism - Wikipedia, the free ... [Last Updated On: August 1st, 2015] [Originally Added On: August 1st, 2015]
- Hypogonadism | Disorders | Knowledge Base [Last Updated On: September 14th, 2015] [Originally Added On: September 14th, 2015]
- Male Hypogonadism - Cleveland Clinic [Last Updated On: October 7th, 2015] [Originally Added On: October 7th, 2015]
- Male hypogonadism Causes - Mayo Clinic [Last Updated On: October 13th, 2015] [Originally Added On: October 13th, 2015]
- Association of hypogonadism with vitamin D status: the ... [Last Updated On: February 15th, 2016] [Originally Added On: February 15th, 2016]
- What Is Low Testosterone? - Male Hypogonadism Symptoms and ... [Last Updated On: February 27th, 2016] [Originally Added On: February 27th, 2016]
- Hypogonadism | University of Maryland Medical Center [Last Updated On: March 11th, 2016] [Originally Added On: March 11th, 2016]
- Male Hypogonadism | Uroweb [Last Updated On: March 21st, 2016] [Originally Added On: March 21st, 2016]
- Hypogonadism | Conditions & Treatments | UCSF Medical Center [Last Updated On: March 29th, 2016] [Originally Added On: March 29th, 2016]
- Hypogonadism - Medscape [Last Updated On: March 29th, 2016] [Originally Added On: March 29th, 2016]
- Treatment Options for Hypogonadism Healthline [Last Updated On: March 29th, 2016] [Originally Added On: March 29th, 2016]
- Hypogonadism Causes Infertility. Learn how to detect and ... [Last Updated On: May 6th, 2016] [Originally Added On: May 6th, 2016]
- Hypogonadism - FPnotebook.com [Last Updated On: May 6th, 2016] [Originally Added On: May 6th, 2016]
- Testosterone treatment of male hypogonadism - UpToDate [Last Updated On: May 6th, 2016] [Originally Added On: May 6th, 2016]
- EFPIA - Hypogonadism [Last Updated On: May 6th, 2016] [Originally Added On: May 6th, 2016]
- Hypogonadism - RightDiagnosis.com [Last Updated On: May 6th, 2016] [Originally Added On: May 6th, 2016]
- Hypogonadotropic hypogonadism - Wikipedia, the free encyclopedia [Last Updated On: May 6th, 2016] [Originally Added On: May 6th, 2016]
- Hypogonadism Symptoms, Diagnosis, Treatments and Causes ... [Last Updated On: June 1st, 2016] [Originally Added On: June 1st, 2016]
- Compare 37 Hypogonadism, Male Medications | Drugs.com [Last Updated On: July 3rd, 2016] [Originally Added On: July 3rd, 2016]
- Male Hypogonadism - Genitourinary Disorders - Merck ... [Last Updated On: July 10th, 2016] [Originally Added On: July 10th, 2016]
- Hypogonadism - Medscape Reference [Last Updated On: July 15th, 2016] [Originally Added On: July 15th, 2016]
- Hypogonadism and Hypogonadism Resources - What is ... [Last Updated On: July 17th, 2016] [Originally Added On: July 17th, 2016]
- Testosterone Deficiency, Hypogonadism | Froedtert Hospital ... [Last Updated On: July 17th, 2016] [Originally Added On: July 17th, 2016]
- Hypogonadism diagnosis - history - Endobible [Last Updated On: July 17th, 2016] [Originally Added On: July 17th, 2016]
- Hypogonadism - Risks, Symptoms and Leading Causes | Treato [Last Updated On: July 17th, 2016] [Originally Added On: July 17th, 2016]
- Lipocine - Hypogonadism [Last Updated On: July 17th, 2016] [Originally Added On: July 17th, 2016]
- Hypogonadism - Definition, Causes, Symptoms and Treatment [Last Updated On: July 17th, 2016] [Originally Added On: July 17th, 2016]
- HIV and Testosterone Deficiency - verywell.com [Last Updated On: July 17th, 2016] [Originally Added On: July 17th, 2016]
- Hypogonadism - UT Medical Center [Last Updated On: July 17th, 2016] [Originally Added On: July 17th, 2016]
- Diagnosis of Hypogonadism: Clinical Assessments and ... [Last Updated On: July 20th, 2016] [Originally Added On: July 20th, 2016]
- Hypogonadism - Wikipedia [Last Updated On: October 25th, 2016] [Originally Added On: October 25th, 2016]
- Hypergonadotropic hypogonadism - Wikipedia [Last Updated On: November 26th, 2016] [Originally Added On: November 26th, 2016]
- Hypogonadism No Moustache! No Beard [Last Updated On: December 7th, 2016] [Originally Added On: December 7th, 2016]
- You & Your Hormones | Endocrine conditions | Male hypogonadism [Last Updated On: December 29th, 2016] [Originally Added On: December 29th, 2016]
- Posters to Be Presented at the Endocrine Society 2017 Annual Meeting - Business Wire (press release) [Last Updated On: February 8th, 2017] [Originally Added On: February 8th, 2017]
- Low Testosterone Products Litigation - US Recall News (press release) [Last Updated On: February 10th, 2017] [Originally Added On: February 10th, 2017]
- Testosterone therapy provides protection against cardiovascular disease in men with low testosterone - Science Daily [Last Updated On: February 15th, 2017] [Originally Added On: February 15th, 2017]
- Hypogonadism in Reproductive Years - Renal and Urology News [Last Updated On: February 15th, 2017] [Originally Added On: February 15th, 2017]
- Latest Research Predicts Endocrinology Drugs Market in Nascent Stage set for advancing growth by 2021 - Satellite PR News (press release) [Last Updated On: February 16th, 2017] [Originally Added On: February 16th, 2017]
- Testosterone therapy may help prevent heart disease - Bel Marra Health [Last Updated On: February 17th, 2017] [Originally Added On: February 17th, 2017]
- Studies show testosterone offers little benefits to aging men - Ars Technica [Last Updated On: February 21st, 2017] [Originally Added On: February 21st, 2017]
- New studies fail to change 'unfavorable balance' of risks/benefits of testosterone supplements - MinnPost [Last Updated On: February 23rd, 2017] [Originally Added On: February 23rd, 2017]
- Testosterone treatment and coronary artery plaque volume in older men with low testosterone - Pharmacy Today, American Pharmacists Association,... [Last Updated On: February 24th, 2017] [Originally Added On: February 24th, 2017]
- A study to evaluate the prevalence of hypogonadism in Indian males with Type-2 diabetes mellitus. - UroToday [Last Updated On: February 27th, 2017] [Originally Added On: February 27th, 2017]
- 8 things you need to know about testosterone and 'the male menopause' - Netdoctor [Last Updated On: February 28th, 2017] [Originally Added On: February 28th, 2017]
- Antares Pharma Announces FDA Acceptance of New Drug Application for Quickshot Testosterone - P&T Community [Last Updated On: February 28th, 2017] [Originally Added On: February 28th, 2017]
- Increased Plaque Volume on CCTA in Older Men Who Use Testosterone Gel - Diagnostic Imaging [Last Updated On: March 1st, 2017] [Originally Added On: March 1st, 2017]
- Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma ... - UroToday [Last Updated On: March 2nd, 2017] [Originally Added On: March 2nd, 2017]
- Declining libido? This may be the cause - Bel Marra Health [Last Updated On: March 3rd, 2017] [Originally Added On: March 3rd, 2017]
- USADA notifies Ben Rothwell of potential anti-doping violation, putting UFC 211 status in jeopardy - MMAjunkie.com [Last Updated On: March 8th, 2017] [Originally Added On: March 8th, 2017]
- Family strength helps Brandon Ramirez persevere - Progress Index [Last Updated On: March 11th, 2017] [Originally Added On: March 11th, 2017]
- TRT and heart health: Conflicting findings published - ModernMedicine [Last Updated On: March 18th, 2017] [Originally Added On: March 18th, 2017]
- Efficacy and safety of testosterone replacement gel for treating hypogonadism in men: Phase III open-label studies. - UroToday [Last Updated On: March 19th, 2017] [Originally Added On: March 19th, 2017]
- Testosterone therapy has positive effects on anthropometric measures, metabolic syndrome components (obesity, lipid ... - UroToday [Last Updated On: March 19th, 2017] [Originally Added On: March 19th, 2017]
- JAMA confirms DTC drove 'Low-T' craze - BioPharma Dive [Last Updated On: March 23rd, 2017] [Originally Added On: March 23rd, 2017]
- Ads for low-testosterone treatments benefit sales but not necessarily health - Science Daily [Last Updated On: March 28th, 2017] [Originally Added On: March 28th, 2017]
- Sport and male sexuality. - UroToday [Last Updated On: March 28th, 2017] [Originally Added On: March 28th, 2017]
- A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management. - UroToday [Last Updated On: April 3rd, 2017] [Originally Added On: April 3rd, 2017]
- Infertility - Causes - NHS Choices [Last Updated On: April 7th, 2017] [Originally Added On: April 7th, 2017]
- Recent research: Male hypogonadism - strategic assessment and ... - WhaTech [Last Updated On: April 15th, 2017] [Originally Added On: April 15th, 2017]
- Testosterone level and endothelial dysfunction in patients with vasculogenic erectile dysfunction. - UroToday [Last Updated On: April 18th, 2017] [Originally Added On: April 18th, 2017]
- XOMA Announces Positive Results from its Phase 2 Proof-Of ... - Yahoo Finance [Last Updated On: April 24th, 2017] [Originally Added On: April 24th, 2017]
- Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms ... - UroToday [Last Updated On: April 25th, 2017] [Originally Added On: April 25th, 2017]
- Global Male Hypogonadism Market, 20162024: Type. Size, Share, Trends & Forecast Report - MilTech [Last Updated On: April 26th, 2017] [Originally Added On: April 26th, 2017]
- Global Male Hypogonadism Market, 20162024: Type. Size, Share, Trends & Forecast Report - satPRnews (press release) [Last Updated On: April 27th, 2017] [Originally Added On: April 27th, 2017]
- Aytu BioScience to Provide Fiscal Third Quarter 2017 Business Update - PR Newswire (press release) [Last Updated On: May 3rd, 2017] [Originally Added On: May 3rd, 2017]
- What's in the Cards for Repros (RPRX) this Earnings Season? - Zacks.com [Last Updated On: May 5th, 2017] [Originally Added On: May 5th, 2017]
- Testosterone Replacement Therapy May Protect Against Stroke, Heart Attack in Hypogonadism - Endocrinology Advisor [Last Updated On: May 5th, 2017] [Originally Added On: May 5th, 2017]
- In Hypogonadism, Stroke May Be Prevented With Testosterone Replacement Therapy - Neurology Advisor [Last Updated On: May 9th, 2017] [Originally Added On: May 9th, 2017]
- AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU) Files An 8-K Entry into a Material Definitive Agreement - Market Exclusive [Last Updated On: May 10th, 2017] [Originally Added On: May 10th, 2017]